AUTHORS
Vinh-Phuc Luu, MD, MSc, Camille Poulon2, Angeline Denouel3, Raju Dangol4, Emmanuelle Jacquot5, Benedicte Calvet6, Glen Lew, MD7
AFFILIATIONS
1 Pierre Fabre Medicament, Boulogne Billancourt, France
2 Pierre Fabre Medicament, Boulogne Billancourt, France
3 Pierre Fabre Medicament, Boulogne Billancourt, France
4 Pierre Fabre Pharmaceuticals, Secaucus, United States
5 Pierre Fabre Medicament, Boulogne Billancourt, France
6 Pierre Fabre Medicament, Boulogne Billancourt, France
7 Pierre Fabre Pharmaceuticals, Secaucus, United States
ABSTRACT
INTRODUCTION
Availability and timely access to treatment is critical for patients with potentially rapid and fatal conditions such as relapsed/refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). Recommended treatment options include EBV-specific cytotoxic T cells (EBV-CTL); however, manufacturing and timely delivery to point-of-care are key challenges. Such advanced therapies can be manufactured in expert academic centers, but not all countries have such centers, and not all can ship cells to where they are needed. Tabelecleucel is an off-the-shelf, allogeneic, GMP-certified, partially HLA-matched EBV-CTL immunotherapy for the treatment of relapsed/refractory EBV+ PTLD. As an advanced cell therapy, its availability depends on manufacturing, product supply, and international distribution logistics. Tabelecleucel is prepared independently of treatment requests and is supported by a drug product inventory with global shipment, aiming to address challenges related to availability and timely access in its approved indication in Europe. We assessed whether the tabelecleucel inventory addresses these challenges in the real-world setting.
METHODS
Treatment request and supply data from European countries were extracted from the ordering platform from inception to 1 July 2026. The treatment request requires the treating healthcare professional to upload patient consent for product lot search, and anonymized patient demographic, transplant and PTLD-related information in the ordering platform. This information includes cytomegalovirus (CMV) serostatus, patient and donor HLA typing information, and suspected origin of the EBV+ PTLD disease (donor or patient). Once the treatment request is completed, the inventory is searched for an appropriate product lot based on the HLA that restricts cytotoxicity, additional compatible HLA types, suspected origin of the EBV+ PTLD disease, and CMV serostatus. The most appropriate product lot is proposed to the requesting healthcare professional who confirms the prescription. After confirmation and ordering by the treating center, product quantity for one full cycle is shipped in liquid nitrogen via international delivery to the treating center for reconstitution by the hospital pharmacist. Under specific circumstances, delivery can be split to accommodate one dose of a cycle per delivery.
Additional cycles of treatment with the same product lot are ordered by the center. If required due to disease evolution, another product lot with a restriction switch may be searched and proposed in a similar process to the initial treatment request.
RESULTS
Of 238 lot requests, 219 (92.0%) led to product lot proposal, while an appropriate product lot was not identified in 19 cases (8.0%). Treatment requests accounted for 202 lot requests and 186 lot proposals, and restriction switches for 31 lot requests and 28 lot proposals. The number of lot deliveries was 209; 111 (53.1%) for treatment requests corresponding to the first cycle, 78 (37.3%) for additional cycles, and 20 (9.6%) for restriction lot switches. The total number of deliveries overall was 410, including 187 full treatment cycles and 223 single doses.
Median time from product lot search to product lot proposal for 214 treatment and switch requests was 22.5 hours (first and third quartiles (Q1–Q3] 7.0–24.0; mean 21.2 hours, standard deviation [SD] 17.84). Median time from order confirmation to delivery (n=238 with available data) was 4.0 business days (Q1–Q3 3.0–5.0; mean 3.9, SD 1.07).
Treatment requests most frequently originated from France (n=84), Italy (61), Belgium (26), Germany (19), and Spain (18) and these countries received the most deliveries: France (n=79), Italy (54), Belgium (25), Germany (20) and Spain (17). The median time from product lot search to product lot proposal was ≤24.5 hours in all countries, and median time from order confirmation to delivery ranged from 3.0 to 5.0 business days for all countries.
CONCLUSIONS
Prospective tabelecleucel lot production covered 92% of need, facilitating rapid turnaround from order confirmation to delivery. Product lot proposals made within 1 business day after lot request, as well as a median time from product lot order to delivery of 4.0 business days, support international shipping from the inventory. The tabelecleucel inventory and shipping platform demonstrates availability and feasibility of timely treatment delivery in the real-world setting in Europe.
DISCLOSURES
Vinh-Phuc Luu, MD, MSc: No relevant conflicts of interest to declare.